

Susanne B Haga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1829331/publications.pdf>

Version: 2024-02-01

91
papers

2,343
citations

186265

28
h-index

233421

45
g-index

92
all docs

92
docs citations

92
times ranked

2767
citing authors

#	ARTICLE	IF	CITATIONS
1	A Systematic Review of the Scope of Study of mHealth Interventions for Wellness and Related Challenges in Pediatric and Young Adult Populations. <i>Adolescent Health, Medicine and Therapeutics</i> , 2022, Volume 13, 23-38.	0.9	6
2	The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine. <i>Journal of Personalized Medicine</i> , 2021, 11, 45.	2.5	7
3	Independent Community Pharmacistsâ€™ Experience in Offering Pharmacogenetic Testing. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 877-886.	0.7	3
4	Delivery of Pharmacogenetic Testing with or without Medication Therapy Management in a Community Pharmacy Setting. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 785-796.	0.7	0
5	Evaluating Primary Care Providersâ€™ Readiness for Delivering Genetic and Genomic Services to Underserved Populations. <i>Public Health Genomics</i> , 2021, , 1-10.	1.0	2
6	Revisiting Secondary Information Related to Pharmacogenetic Testing. <i>Frontiers in Genetics</i> , 2021, 12, 741395.	2.3	7
7	Clinical Utilization of Pharmacogenetics in Psychiatry â€“ Perspectives of Pharmacists, Genetic Counselors, Implementation Science, Clinicians, and Industry. <i>Pharmacopsychiatry</i> , 2020, 53, 162-173.	3.3	16
8	Individualizing pharmacogenomic test results in the context of the microbiome. <i>Personalized Medicine</i> , 2020, 17, 459-468.	1.5	1
9	The enduring importance of family health history in the era of genomic medicine and risk assessment. <i>Personalized Medicine</i> , 2020, 17, 229-239.	1.5	5
10	Toward digital-based interventions for medication adherence and safety. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 735-746.	2.4	9
11	Promoting Wellness Through Mobile Health Technology in a College Student Population: Protocol Development and Pilot Study. <i>JMIR Research Protocols</i> , 2020, 9, e16474.	1.0	1
12	Pharmacogenomics courses in pharmacy school curricula. <i>Pharmacogenomics</i> , 2019, 20, 625-630.	1.3	28
13	Access to Genetic Counselors in the Southern United States. <i>Journal of Personalized Medicine</i> , 2019, 9, 33.	2.5	31
14	Patient characteristics, experiences and perceived value of pharmacogenetic testing from a single testing laboratory. <i>Pharmacogenomics</i> , 2019, 20, 581-587.	1.3	5
15	A stepwise approach to implementing pharmacogenetic testing in the primary care setting. <i>Pharmacogenomics</i> , 2019, 20, 1103-1112.	1.3	27
16	Managing Increased Accessibility to Pharmacogenomic Data. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 922-924.	4.7	4
17	<p>Pharmacogenomic Testing In Pediatrics: Navigating The Ethical, Social, And Legal Challenges</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2019, Volume 12, 273-285.	0.7	4
18	Awareness of family health history in a predominantly young adult population. <i>PLoS ONE</i> , 2019, 14, e0224283.	2.5	13

#	ARTICLE	IF	CITATIONS
19	First Responder to Genomic Information: A Guide for Primary Care Providers. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 459-466.	3.8	7
20	Primary Care Physicians's Knowledge, Attitudes, and Experience with Personal Genetic Testing. <i>Journal of Personalized Medicine</i> , 2019, 9, 29.	2.5	58
21	Foundations and Application of Precision Medicine. , 2019, , 21-45.		0
22	Effects of Delivering <i>SLCO1B1</i> Pharmacogenetic Information in Randomized Trial and Observational Settings. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002228.	3.6	40
23	Qualitative user evaluation of a revised pharmacogenetic educational toolkit. <i>Pharmacogenomics and Personalized Medicine</i> , 2018, Volume 11, 139-146.	0.7	10
24	Horizon Scan Of Clinical Laboratories Offering Pharmacogenetic Testing. <i>Health Affairs</i> , 2018, 37, 717-723.	5.2	43
25	Update: looking beyond the 100,000 Genome Project. <i>Personalized Medicine</i> , 2017, 14, 85-87.	1.5	6
26	Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy setting. <i>Pharmacogenomics</i> , 2017, 18, 327-335.	1.3	14
27	Primary care providers' use of pharmacist support for delivery of pharmacogenetic testing. <i>Pharmacogenomics</i> , 2017, 18, 359-367.	1.3	21
28	Introducing personalized health for the family: the experience of a single hospital system. <i>Pharmacogenomics</i> , 2017, 18, 1589-1594.	1.3	8
29	Considering the Benefits and Risks of Research Participants' Access to Sequence Data. <i>Genetic Testing and Molecular Biomarkers</i> , 2017, 21, 717-721.	0.7	1
30	Informational Quest. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	1
31	Integrating pharmacogenetic testing into primary care. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 327-336.	0.7	7
32	Educating patients and providers through comprehensive pharmacogenetic test reports. <i>Pharmacogenomics</i> , 2017, 18, 1047-1050.	1.3	14
33	Development and Initial Assessment of a Patient Education Video about Pharmacogenetics. <i>Journal of Personalized Medicine</i> , 2017, 7, 4.	2.5	22
34	Proposal for a pharmacogenetics certificate program for pharmacists. <i>Pharmacogenomics</i> , 2016, 17, 535-539.	1.3	6
35	Considerations of pharmacogenetic testing in children. <i>Pharmacogenomics</i> , 2016, 17, 975-977.	1.3	3
36	Evaluation of a pharmacogenetic educational toolkit for community pharmacists. <i>Pharmacogenomics</i> , 2016, 17, 1491-1502.	1.3	15

#	ARTICLE	IF	CITATIONS
37	A review of consent practices and perspectives for pharmacogenetic testing. <i>Pharmacogenomics</i> , 2016, 17, 1595-1605.	1.3	17
38	Patient experiences with pharmacogenetic testing in a primary care setting. <i>Pharmacogenomics</i> , 2016, 17, 1629-1636.	1.3	38
39	Challenges of development and implementation of point of care pharmacogenetic testing. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 949-960.	3.1	27
40	Rationale and design of the <i>SLCO1B1</i> genotype guided statin therapy trial. <i>Pharmacogenomics</i> , 2016, 17, 1873-1880.	1.3	4
41	Clinical and Counseling Experiences of Early Adopters of Whole Exome Sequencing. <i>Journal of Genetic Counseling</i> , 2016, 25, 337-343.	1.6	13
42	Community pharmacists' experience with pharmacogenetic testing. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2015, 55, 587-594.	1.5	34
43	Interprofessional education for personalized medicine through technology-based learning. <i>Personalized Medicine</i> , 2015, 12, 237-243.	1.5	4
44	Challenges to Integrating Pharmacogenetic Testing into Medication Therapy Management. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 346-352.	0.9	19
45	Nurses' communication of pharmacogenetic test results as part of discharge care. <i>Pharmacogenomics</i> , 2015, 16, 251-256.	1.3	10
46	Potential use of auxiliary labels to promote patient awareness of pharmacogenetic testing. <i>Pharmacogenomics</i> , 2015, 16, 299-301.	1.3	2
47	Incorporation of pharmacogenetic testing into medication therapy management. <i>Pharmacogenomics</i> , 2015, 16, 1931-1941.	1.3	35
48	Information Seeking and Sharing Behavior Following Genomic Testing for Diabetes Risk. <i>Journal of Genetic Counseling</i> , 2015, 24, 58-66.	1.6	16
49	Genetically Guided Statin Therapy on Statin Perceptions, Adherence, and Cholesterol Lowering: A Pilot Implementation Study in Primary Care Patients. <i>Journal of Personalized Medicine</i> , 2014, 4, 147-162.	2.5	31
50	Promoting the participant-researcher partnership. <i>Genetics in Medicine</i> , 2014, 16, 228-230.	2.4	4
51	Delivering pharmacogenetic testing to the masses: an achievable goal?. <i>Pharmacogenomics</i> , 2014, 15, 1-4.	1.3	6
52	Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting. <i>Pharmacogenomics</i> , 2014, 15, 1677-1686.	1.3	30
53	Comparison of delivery strategies for pharmacogenetic testing services. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 139-145.	1.5	43
54	Public Trust in Genomic Risk Assessment for Type 2 Diabetes Mellitus. <i>Journal of Genetic Counseling</i> , 2014, 23, 401-408.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Genomic Counseling: Next Generation Counseling. <i>Journal of Genetic Counseling</i> , 2014, 23, 689-692.	1.6	26
56	Striking a balance in communicating pharmacogenetic test results: Promoting comprehension and minimizing adverse psychological and behavioral response. <i>Patient Education and Counseling</i> , 2014, 97, 10-15.	2.2	25
57	Promoting Public Awareness and Engagement in Genome Sciences. <i>Journal of Genetic Counseling</i> , 2013, 22, 508-516.	1.6	12
58	Public Knowledge of and Attitudes Toward Genetics and Genetic Testing. <i>Genetic Testing and Molecular Biomarkers</i> , 2013, 17, 327-335.	0.7	195
59	Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists. <i>Pharmacogenomics</i> , 2013, 14, 957-968.	1.3	66
60	Primary-care physicians' access to genetic specialists: an impediment to the routine use of genomic medicine?. <i>Genetics in Medicine</i> , 2013, 15, 513-514.	2.4	26
61	Stakeholder Views on Returning Research Results. <i>Advances in Genetics</i> , 2013, 84, 41-81.	1.8	19
62	Pharmacogenetic testing: current evidence of clinical utility. <i>Therapeutic Advances in Drug Safety</i> , 2013, 4, 155-169.	2.4	30
63	100k Genome Project: sequencing and much more. <i>Personalized Medicine</i> , 2013, 10, 761-764.	1.5	3
64	Overview of Policy, Ethical and Social Considerations in Genomic and Personalized Medicine. , 2013, , 392-404.		2
65	Delivering pharmacogenetic testing in a primary care setting. <i>Pharmacogenomics and Personalized Medicine</i> , 2013, 6, 105.	0.7	37
66	Enhancing geneticists' perspectives of the public through community engagement. <i>Genetics in Medicine</i> , 2012, 14, 243-249.	2.4	23
67	Professional Perspectives About Pharmacogenetic Testing and Managing Ancillary Findings. <i>Genetic Testing and Molecular Biomarkers</i> , 2012, 16, 21-24.	0.7	49
68	Public Perspectives About Pharmacogenetic Testing and Managing Ancillary Findings. <i>Genetic Testing and Molecular Biomarkers</i> , 2012, 16, 193-197.	0.7	55
69	Conference Scene: Is personalized medicine ready for prime time?. <i>Personalized Medicine</i> , 2012, 9, 475-478.	1.5	1
70	Primary care physicians' knowledge of and experience with pharmacogenetic testing. <i>Clinical Genetics</i> , 2012, 82, 388-394.	2.0	219
71	Insurance Coverage Policies for Personalized Medicine. <i>Journal of Personalized Medicine</i> , 2012, 2, 201-216.	2.5	82
72	Characterization of clinical study populations by race and ethnicity in biomedical literature. <i>Ethnicity and Disease</i> , 2012, 22, 96-101.	2.3	13

#	ARTICLE	IF	CITATIONS
73	Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditions. <i>Genetics in Medicine</i> , 2011, 13, 723-728.	2.4	47
74	Consideration of patient preferences and challenges in storage and access of pharmacogenetic test results. <i>Genetics in Medicine</i> , 2011, 13, 887-890.	2.4	19
75	Genomic Risk Profiling: Attitudes and Use in Personal and Clinical Care of Primary Care Physicians Who Offer Risk Profiling. <i>Journal of General Internal Medicine</i> , 2011, 26, 834-840.	2.6	64
76	Considerations for the Impact of Personal Genome Information: A Study of Genomic Profiling among Genetics and Genomics Professionals. <i>Journal of Genetic Counseling</i> , 2010, 19, 387-401.	1.6	28
77	Researcher Practices on Returning Genetic Research Results. <i>Genetic Testing and Molecular Biomarkers</i> , 2010, 14, 821-827.	0.7	32
78	Impact of limited population diversity of genome-wide association studies. <i>Genetics in Medicine</i> , 2010, 12, 81-84.	2.4	96
79	Genome Policy Considerations for Genomic Medicine. , 2010, , 209-222.		0
80	Analysis of Educational Materials and Destruction/Opt-Out Initiatives for Storage and Use of Residual Newborn Screening Samples. <i>Genetic Testing and Molecular Biomarkers</i> , 2010, 14, 587-592.	0.7	12
81	Ethical Issues of Predictive Genetic Testing for Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2009, 3, 781-788.	2.2	16
82	Ensuring the Safe Use of Genomic Medicine in Children. <i>Clinical Pediatrics</i> , 2009, 48, 703-708.	0.8	7
83	From Sequence to Genomic Medicine: Genome Policy Considerations. , 2009, , 388-400.		1
84	Pharmacogenetic testing: not as simple as it seems. <i>Genetics in Medicine</i> , 2008, 10, 391-395.	2.4	64
85	Ethical, Legal, and Social Implications of Biobanks for Genetics Research. <i>Advances in Genetics</i> , 2008, 60, 505-544.	1.8	118
86	Prescribing BiDil. <i>Journal of the American College of Cardiology</i> , 2006, 48, 12-14.	2.8	31
87	Genomics-based labeling and attribution: a case for integrating social sciences into personalized medicine research. <i>Personalized Medicine</i> , 2006, 3, 317-323.	1.5	0
88	Adding pharmacogenetics information to drug labels: lessons learned. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 847-854.	1.5	46
89	Teaching resources for genetics. <i>Nature Reviews Genetics</i> , 2006, 7, 223-229.	16.3	29
90	Defining the spectrum of genome policy. <i>Nature Reviews Genetics</i> , 2006, 7, 966-972.	16.3	20

#	ARTICLE	IF	CITATIONS
91	Translating genomic biomarkers into clinically useful diagnostics. Expert Review of Molecular Diagnostics, 2006, 6, 179-191.	3.1	51